Kotwica-Mojzych
Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of malignant plasma cells in bone marrow, bone lesions, renal failure and immunodeficiency. The certain impact on the prognosis is associated with phenotype of malignant plasma cells. Membrane glycoproteins CD200, CD27, CD70 and CD40 represent the markers associated with immune escape and malignancy of plasma cells in multiple myeloma. MM patients with cells overexpressing CD200 have shorter event free survival (EFS) when compared with patients whose cells do not (over) express CD200. Loss of expression of CD27 and overexpression both CD70 and CD40 are reported to be characteristic for aggressive MM. Blockade of the expression of CD200, CD70 and CD40 became an adjuvant therapy for the treatment of multiple myeloma. In summary, the further analysis of the phenotype of malignant plasma cells make bring a useful tool for management in multiple myeloma.
